Trial Profile
PD-1 Inhibition With Nivolumab for the Treatment of Patients With Acute Myeloid Leukemia in Remission at High Risk for Relapse
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 31 Aug 2023 Status changed from active, no longer recruiting to completed.
- 12 May 2023 Planned End Date changed from 31 Oct 2022 to 31 Oct 2023.
- 12 May 2023 Planned primary completion date changed from 31 Oct 2022 to 31 Oct 2023.